Female Osteoporosis (OST and ORAI)

Performance of the Osteoporosis Self-Assessment Tool (OST) and Osteoporosis Risk Assessment Index (ORAI) in Predicting Osteoporosis in Postmenopausal Turkish Women

The aim of this study is to compare the Osteoporosis Risk Assessment Tool and the Osteoporosis Self-Assessment Tool with the gold standard DEXA in determining the risk of osteoporosis in the lumbar and femoral regions in female individuals in the Turkish population, and to investigate their sensitivity and specificity in the first stage of screening for the detection of female osteoporosis.

Study Overview

• Status: Not yet recruiting
• Conditions: Female Osteoporosis

Detailed Description

This study will be conducted as a single-center, retrospective study at the Physical Medicine and Rehabilitation Clinic of Kayseri City Hospital between January 2024 and January 2025. This study will include female patients aged 50-75 who underwent osteoporosis screening with DEXA at the Kayseri City Hospital FTR outpatient clinics between January 2021 and January 2024. Patient data will be obtained retrospectively from the hospital database. Sociodemographic data (age, height, weight, body mass index) and current laboratory data (complete blood count, biochemical values (fasting blood sugar, BUN, creatinine, AST, ALT, calcium, phosphorus, alkaline phosphatase, total protein, albumin, parathyroid hormone, vitamin D3, T4, TSH), and DEXA values (bone mineral density, lumbar vertebrae, and femoral neck and total femur T scores) will be recorded. The OST score will be calculated using body weight and age parameters. The ORAI score will be calculated using age, weight, and estrogen use from hospital data.

The data will be evaluated using the SPSS 24.0 software package. Descriptive statistical analyses will include calculations of mean, standard deviation, frequency, and percentages. In comparative statistics, the Student T-test or Mann Whitney U-test will be used to compare independent groups. Chi-square analysis will be applied to compare categorical variables. Pearson or Spearman correlation analyses will be applied to evaluate the relationship between variables. Both groups will be compared, and p<0.05 will be considered statistically significant.

• Study Type: Observational
• Enrollment (Estimated): 1500

Contacts and Locations

• Study Contact: Name: Fatma Gül Ülkü Demir, MD; Phone Number: +903523157700; Email: mdfgudemir@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

This study will include female patients aged 50-75 who underwent osteoporosis screening with DEXA at the Kayseri City Hospital FTR outpatient clinics between January 2021 and January 2024.

Description

Inclusion criteria:

• Postmenopausal women aged 50-75
• Patients who underwent imaging with the STRATOS DEXA device at Kayseri City Hospital

Exclusion criteria:

• Patients younger than 50 or older than 75 years of age
• Patients with secondary osteoporosis
• Male patients
• Patients with uncontrolled severe comorbid conditions
• Patients with a history of pathological fractures

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
female osteoporosis group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dual-energy X-ray absorptiometry (DEXA)	Dual-energy X-ray absorptiometry (DEXA)	January 2021 - January 2024
Osteoporosis Self-Assessment Tool (OST)	Osteoporosis Self-Assessment Tool (OST)	January 2021 - January 2024
Osteoporosis Risk Assessment Index (ORAI)	Osteoporosis Risk Assessment Index (ORAI)	January 2021 - January 2024

Collaborators and Investigators

• Sponsor: Kayseri City Hospital
• Investigators: Principal Investigator: Fatma Gül Ülkü Demir, MD, Kayseri City Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): February 4, 2026
• Primary Completion (Estimated): February 4, 2026
• Study Completion (Estimated): July 15, 2026

Study Registration Dates

• First Submitted: February 4, 2026
• First Submitted That Met QC Criteria: February 4, 2026
• First Posted (Actual): February 11, 2026

Study Record Updates

• Last Update Posted (Actual): February 11, 2026
• Last Update Submitted That Met QC Criteria: February 4, 2026
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Keywords: OST; female osteoporosis; ORAI
• Other Study ID Numbers: Female osteoporosis

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: There is not a plan to make IPD available.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No